Omics-based insights into therapy failure of pediatric B-lineage acute lymphoblastic leukemia

Abstract

B-lineage acute lymphoblastic leukemia (B-ALL) is the most common type of cancer seen in children and is characterized by a variable clinical course. Although there have been remarkable improvements in the therapy outcomes of pediatric B-ALL, treatment failure remains the leading-cause of death in 18% of the afflicted patients during the first 5 years after diagnosis. Molecular heterogeneities of pediatric B-ALL play important roles as determinants of the therapy response. Therefore, many of these molecular abnormalities have an established prognostic value in the disease. The present review discusses the omics-based revelations from epigenomics, genomics, transcriptomics and proteomics about treatment failure in pediatric B-ALL. Next it highlights the promise of the molecular aberration-targeted therapy to improve the treatment outcomes.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2019-09-10
Info
Issue
Section
Reviews
Keywords:
Pediatric B-ALL, therapy failure, omics.
Statistics
  • Abstract views: 576

  • PDF: 438
  • HTML: 13
How to Cite
Alsagaby, S. A. (2019). Omics-based insights into therapy failure of pediatric B-lineage acute lymphoblastic leukemia. Oncology Reviews, 13(2). https://doi.org/10.4081/oncol.2019.435